Biogen (NASDAQ:BIIB) and Crispr Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Biogen and Crispr Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 40.96% 46.51% 23.42%
Crispr Therapeutics 23.09% 14.98% 11.71%

Volatility and Risk

Biogen has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Crispr Therapeutics has a beta of 3.25, suggesting that its stock price is 225% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of Biogen shares are held by institutional investors. Comparatively, 50.0% of Crispr Therapeutics shares are held by institutional investors. 0.4% of Biogen shares are held by insiders. Comparatively, 21.4% of Crispr Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Biogen and Crispr Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 3 20 11 0 2.24
Crispr Therapeutics 0 1 13 0 2.93

Biogen presently has a consensus price target of $316.69, suggesting a potential downside of 4.90%. Crispr Therapeutics has a consensus price target of $80.41, suggesting a potential upside of 44.10%. Given Crispr Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Crispr Therapeutics is more favorable than Biogen.

Valuation and Earnings

This table compares Biogen and Crispr Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biogen $14.38 billion 4.03 $5.89 billion $33.57 9.92
Crispr Therapeutics $289.59 million 11.72 -$164.98 million $1.17 47.69

Biogen has higher revenue and earnings than Crispr Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Crispr Therapeutics, indicating that it is currently the more affordable of the two stocks.

Biogen Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.



Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.



Source link